You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 123 No. 3, March 2005 TABLE OF CONTENTS
  Archives
  •  Online Features
  Clinicopathologic Reports, Case Reports, and Small Case Series
 This Article
 •Full text
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (18)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Men's Health
 •Men's Sexual Function
 •Neurology
 •Neuro-ophthalmology
 •Ophthalmological Disorders, Other
 •Drug Therapy
 •Adverse Effects
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Recurrent Visual Field Defect and Ischemic Optic Neuropathy Associated With Tadalafil Rechallenge

Arch Ophthalmol. 2005;123:400-401.

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Tadalafil, a selective cyclic guanosine monophosphate (cGMP)–specific phosphodiesterase type 5 (PDE5) inhibitor, enhances penile erectile function in men. Nitric oxide along with cGMP promotes blood flow to and dilation of smooth muscle in the corpus cavernosum of the penis. Phosphodiesterase type 5 inhibitors prevent degradation of cGMP to potentiate erectile function. Tadalafil (Cialis; Lily ICOS LLC, Indianapolis, Ind) is one of the PDE5 inhibitors approved for erectile dysfunction, which also include sildenafil citrate (Viagra; Pfizer, Inc, New York, NY) and vardenafil hydrochloride (Levitra; Bayer AG, Leverkusen, Germany, and GlaxoSmithKline, Uxbridge, England).

The package insert for tadalafil describes adverse ophthalmic reactions that include blurred vision, changes in color vision, conjunctivitis, eye pain, tearing, and swelling of the eyelids. Some reports suggest that sildenafil use may be associated with nonarteritic anterior ischemic optic neuropathy (NAION).1-3 We describe a patient who took tadalafil 5 times in 1 month. He developed transient inferior visual . . . [Full Text of this Article]

Report of a Case


Comment

AUTHOR INFORMATION
Kathryn Bollinger, MD, PhD; Michael S. Lee, MD



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Non-arteritic anterior ischaemic optic neuropathy and phosphodiesterase-5 inhibitors
Hayreh
Br J Ophthalmol 2008;92:1577-1580.
FULL TEXT  

Hypothesis: A Venous Etiology for Nonarteritic Anterior Ischemic Optic Neuropathy
Levin and Danesh-Meyer
Arch Ophthalmol 2008;126:1582-1585.
FULL TEXT  

Erectile dysfunction drugs and risk of anterior ischaemic optic neuropathy: casual or causal association?
Danesh-Meyer and Levin
Br J Ophthalmol 2007;91:1551-1555.
ABSTRACT | FULL TEXT  

Can erectile dysfunction drug use lead to ischaemic optic neuropathy?
Pomeranz
Br J Ophthalmol 2006;90:127-128.
FULL TEXT  

BJO at a glance
Hoyt
Br J Ophthalmol 2006;90:127-127.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2005 American Medical Association. All Rights Reserved.